Bas Thijssen

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

Ron J. Keizer, Robert S. Jansen, Hilde Rosing et al. · Pharmacology Research & Perspectives · 2015 · 196 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +16

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens et al. · British Journal of Cancer · 2020 · 51 citations · Full text

Medicine, Oncology, Pharmacology +16

A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry

Jeroen J. M. A. Hendrikx, M. J. X. Hillebrand, Bas Thijssen et al. · Journal of Chromatography B · 2011 · 48 citations

Medicine, Pharmacokinetics, Pharmacology +10

A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry

Liia D. Vainchtein, Bas Thijssen, Ellen Stokvis et al. · Biomedical Chromatography · 2005 · 46 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen et al. · Cancer Chemotherapy and Pharmacology · 2020 · 44 citations · Full text

Medicine, Oncology, Pharmacology +14